D-amphetamine and delinquency: hyperkinesis persisting?
The clinical efficacy of d-amphetamine for delinquent behavior in adolescents and the relationships between such delinquency and hyperactivity of childhood were explored employing the methods of sequential analysis. Fourteen subject pairs of delinquent teenagers were examined, and a significant positive effect documented for d-amphetamine as compared to placebo when both were added to an ongoing psychotherapeutic regimen. Tolerance, withdrawal, and euphoria were not associated with d-amphetamine's use in the experimental subjects. Parallels were drawn between d-amphetamine' s effects in delinquent adolescents and hyperactive children; a re-analysis of the data demonstrated surprisingly close links between a history or presence of hyperactive traits and a clinical response to d-amphetamine. Difficulties in employing d-amphetamine in this age group are acknowledged and suggestions for further research offered. The notion that children "outgrow" hyperactivity may be simplistic: hyperactive children as teenagers may not be overly active; however, they continue to manifest behavioral difficulties, primarily of an antisocial nature. While this may be partially explained on the basis of negative aspects in their upbringing, there is some evidence of hereditary and neurologic mechanisms at fault. One method of documenting continuing neurologic dysfunction in the hyperactive child turned teenager is by direct examination. A number of investigators have demonstrated electroencephalographic abnormalities in juvenile delinquents, many of whom had histories of hyperactivity as children. More recently, this kind of individual has been shown to suffer some frontal lobe dysfunction and to manifest subtle, but definite, abnormalities on intensive neurological examination. Continuing central nervous system dysfunction in delinquency might also be demonstrated by pharmacologic means: should delinquent adolescents respond to drugs that help the hyperactive child, similar mechanisms might be responsible. The early uncontrolled studies of Hill in this regard (summarized in 1947), suggesting that d, l-amphetamine was helpful with some delinquent adolescents, seem largely to have been forgotten. Hill believed that among a large group of delinquents, some, characterized by impulsive irritability, violence, late cessation of nocturnal eneuresis, and a familial history of epilepsy, benefited by a reduction of impulsivity with amphetamine; both early and recent workers remark on a similar reduction in impulsivity when stimulants are successfully used in younger hyperactive children. Eisenberg and coworkers have reported the only controlled study of stimulants in delinquency. These investigators found d-amphetamines superior to placebo on teachers' and cottage-parents' ratings in institutionalized Negro boys. Unfortunately, much of the statistical work in this report is uneven because of factors beyond the control of the researchers. Moreover, an unvalidated symptom check list was employed with no report of which specific symptoms were improved with the drug and which not. The present report attempts a further analysis of stimulants in delinquency. It is constructed to answer the following questions: 1. Is d-amphetamine significantly superior to placebo in controlling delinquent behavior? 2. Are there specific symptom clusters for which d-amphetamine is especially helpful? Thus, is there a prototypical delinquent responder to d-amphetamine? 3. If so, is this information helpful in assessing the association between hyperactivity of childhood and delinquency of adolescence?
Maletzky
B M
BM
Department of Psychiatry and Neurology, US Lyster Army Hospital, Fort Rucker, Alabama, USA.
D000293:Adolescent; D000294:Adolescent Behavior / Q000187:drug effects*; D000374:Aggression; D000987:Antisocial Personality Disorder / Q000188:drug therapy* / Q000523:psychology; D003913:Dextroamphetamine / Q000627:therapeutic use*; D006801:Humans; D007398:Interpersonal Relations; D007604:Juvenile Delinquency / Q000517:prevention & control*; D008297:Male; D016037:Single-Blind Method; D016896:Treatment Outcome
D003913:Dextroamphetamine